| Description | Lamifiban is a nonpeptide glycoprotein IIb/IIIa antagonist. It prevents platelet loss during experimental cardiopulmonary bypass. |
| Synonyms | Ro-44-9883/000, Ro 44-9883/000, Ro44-9883/000 |
| molecular weight | 468.5 |
| Molecular formula | C24H28N4O6 |
| CAS | 144412-49-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Global Organization Network (PARAGON)-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation. 2002 Jan 22;105(3):316-21. PubMed PMID: 11804986. 2. Dooley M, Goa KL. Lamifiban. Drugs. 1999 Feb;57(2):215-21; discussion 222-3. Review. PubMed PMID: 10188762. 3. Théroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation. 1996 Sep 1;94(5):899-905. PubMed PMID: 8790023. 4. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol. 1998 Dec;32(7):2003-10. PubMed PMID: 9857885. |